E-resources
Peer reviewed
Open access
-
Shoji, Sunao; Nakano, Mayura; Fujikawa, Hiroshi; Endo, Kazuyuki; Hashimoto, Akio; Tomonaga, Tetsuro; Terachi, Toshiro; Uchida, Toyoaki
International journal of urology, November 2015, Volume: 22, Issue: 11Journal Article
Objectives To evaluate longitudinal changes in urinary function and quality of life, and the oncological outcomes of patients treated with urethra‐sparing high‐intensity focused ultrasound for localized prostate cancer. Methods Patients with negative findings in the urethra and the anterior urethral zone using transrectal ultrasound‐guided targeted biopsies, and magnetic resonance imaging, received urethra‐sparing or whole‐gland high‐intensity focused ultrasound as the primary therapy for localized prostate cancer without transurethral resection of the prostate. Longitudinal changes in urinary function and quality of life, and the oncological outcomes of the patients were analyzed retrospectively. Results The median follow‐up times for urethra‐sparing and whole‐gland high‐intensity focused ultrasound were 36 and 30 months, respectively. Comparing the patients treated with urethra‐sparing high‐intensity focused ultrasound (n = 45) with those treated with whole‐gland high‐intensity focused ultrasound (n = 65), there were significant differences in the International Prostate Symptom Score (P = 0.014) at 3 months, International Prostate Symptom Score quality of life (P = 0.033) at 3 months, maximum urinary flow rate (mL/s; at 3 months, P = 0.010; at 6 months, P = 0.038) and residual urine volume (mL; at 3 months, P < 0.0001; at 6 months, P = 0.016; at 12 months, P = 0.028). For quality of life, there were significant differences in Functional Assessment of Cancer Therapy – General (at 3 months, P = 0.022) and Functional Assessment of Cancer Therapy – Prostate (at 3 months, P = 0.028; at 6 months, P = 0.034). There were no significant differences in oncological outcomes regarding negative biopsy rates on follow up (91% vs 92%; P = 0.8) or biochemical disease‐free survival rates (86.7% vs 89.2%; P = 0.7). Conclusions Urethra‐sparing high‐intensity focused ultrasound might prevent prolonged bladder outlet obstruction, and could be a treatment option for localized prostate cancer.
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.